Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — FY2024 Earnings Presentation
18 slides from Fresenius Medical Care's earnings presentation, Feb 25, 2025
Slide 1: Annual Press Conference 2025
Helen Giza CEO & Chair of the Management Board February 25, 2025 Annual Press Conference 2025
Slide 2: Safe harbor statement
Safe harbor statement: In this Safe harbor statement, “the Company” and “Fresenius Medical Care” refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conve
Slide 3: We are the leading global kidney care company
We are the leading global kidney care company ▪ We are the market leader in products and services. ▪ We aim to improve our patients’ quality of life by offering them high-quality products and treatments. ▪ We sell products in more than 150 countries. ▪ We are around 112,000 employees worldwide. Crea
Slide 4: Our operating model leverages the advantages of vertical integration
Our operating model leverages the advantages of vertical integration ius Medical en Ca s re re F Focus on Early access to innovation in value creation Predictability and scale in dialysis MedTech in both businesses supply chain Leverage infrastructure and global G&A Care Delivery Care Enablement Lev
Slide 5: Achievements
Achievements
Slide 6: 2024: second year of focused execution
2024 •In a second year of focused execution, Fresenius Medical Care delivered on its commitments, meeting the top end of the •operating income target, realizing savings •ahead of plan and advancing our ambitious •portfolio optimization.
Slide 7: Milestones 2023-2024: Entering the final phase of our three-year transformation journey
Milestones 2023-2024 | Entering the final phase of our three-year transformation journey Received U.S. Executed on Dividend Simplified approval for FME25 and increase of governance industry-leading realized 21% to EUR structure through 5008X sustainable 1.44 per legal form hemodialysis savings share
Slide 8: Strengthened financial performance driving enhanced value creation
Strengthened financial performance driving enhanced value creation MARGIN IMPROVEMENT ON TRACK FME25 SAVINGS AHEAD OF PLAN Operating income margin Accumulated FME25 savings in € million 750 9,5% 9,7% 10,3% 9,3% Group 567 7,9% 8,1% Care Delivery 6,1% 2,3% Care Enablement 346 1,9% 131 2022 2023 2024 2
Slide 9: 2024 | Further divestitures closed as execution of plan continues
2024 | Further divestitures closed as execution of plan continues Portfolio optimization plan as presented in 2023 Divestments of non-core and margin dilutive assets as part of ongoing portfolio optimization plan Closed divestments: ▪ CD and CE operations in Argentina ✓ ▪ CD operations in Chile, Col
Slide 10: Financials
ae FRESENIUS f EDICAL.CARE o Gq : ay | = =
Slide 11: 2024 | Organic revenue growth and margin further improved
2024 | Organic revenue growth and margin further improved Revenue | outlook base1 Operating income | outlook base1 in € million Margin in % outlook base1 7.0% 8.1% 9.3% 7.2% +2.1% outlook base1 19.454 19.049 19.454 19.336 17.6% +4.1% -405 organic2 -118 1.812 171 1.540 -15 1.369 1.392 -405 FY 2023 Di
Slide 12: 2024 | Care Delivery continued organic growth and improved margin
2024 | Care Delivery continued organic growth and improved margin Revenue | outlook base1 Operating income | outlook base1 in € million Margin in % outlook base1 outlook base1 9.7% 10.3% +6.4% +1.2% 60 15,158 +3.7% 15,337 288 -253 1.572 1.477 organic2 12.333 12.812 U.S. 2.825 2.525 International FY
Slide 13: 2024 | Care Enablement strongly increased operating income margin
2024 | Care Enablement strongly increased operating income margin Revenue | outlook base1 Operating income | outlook base1 in € million in € million Margin in % outlook base1 2.3% 6.1% +5.0% outlook base1 +4.8% 5.618 +184.4% 5.353 organic2 -58 344 131 150 121 FY 2023 FY 2024 FY 2023 Business FME Sav
Slide 14: Outlook
Outlook
Slide 15: Outlook | FY 2025 | Strong earnings growth
Outlook | FY 2025 | Strong earnings growth FY 2025 Revenue & Operating Income Positive to a low-single digit Revenue percent growth FY 2024 basis: EUR 19,336 million Implied Group Operating Income Margin around 11% to 12% High-teens to high-twenties Operating percent growth Income FY 2024 basis: EUR
Slide 16: FME bringing a new standard of care to the U.S. with expansion of High-Volume Hemodiafiltration
FME bringing a new standard of care to the U.S. with expansion of High- Volume Hemodiafiltration Leveraging benefits of a vertically integrated company Care Delivery Care Enablement ▪ Opportunity to positively affect quality of life, improve ▪ Opportunity to bring novel advanced therapy to U.S. outc
Slide 17: 2025 | Another successful year to come
2025 | Another successful year to come ▪ Continued execution and finalization of our turnaround and transformation plan. ▪ As a vertically integrated company, we will further redefine the standards of care for patients with renal disease by delivering exceptional products. ▪ On track for the launch
Slide 18: Questions please
Dall we FRESENI! vy MEDICAL
Fresenius Medical Care — FY2024 Earnings Presentation on 6ix